Assenagon Asset Management
LRMR icon

Assenagon Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Assenagon Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-256,861
Closed -$742K – 1229
2025
Q2 		$742K Buy
256,861
+38,427
+18% +$89K ﹤0.01% 975
2025
Q1 		$470K Sell
218,434
-1,553
-0.7% -$4.91K ﹤0.01% 1026
2024
Q4 		$851K Sell
219,987
-6,488
-3% -$42.8K ﹤0.01% 1128
2024
Q3 		$1.48M Sell
226,475
-383,554
-63% -$3.08M ﹤0.01% 1040
2024
Q2 		$4.42M Sell
610,029
-26,156
-4% -$200K 0.01% 671
2024
Q1 		$4.83M Buy
+636,185
New +$4.96M 0.01% 615
2019
Q3 		– Sell
-36,565
Closed -$522K – 962
2019
Q2 		$522K Buy
36,565
+18,190
+99% +$485K ﹤0.01% 844
2019
Q1 		$604K Buy
+18,375
New +$942K 0.01% 787

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Assenagon Asset Management's LRMR Position: Q3 2025 in Review

Assenagon Asset Management sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 256,861 shares — an estimated $742K sold.

Assenagon Asset Management first reported a position in LRMR in Q1 2019 and held it in 8 quarters. The position peaked at $4.83M in Q1 2024. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • Assenagon Asset Management reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 256,861 Larimar Therapeutics shares in Q3 2025, an estimated $742K.
  • Assenagon Asset Management first reported a position in Larimar Therapeutics in Q1 2019 and held it in 8 quarters.
  • Assenagon Asset Management's Larimar Therapeutics position peaked at $4.83M in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on Assenagon Asset Management's 13F filing for Q3 2025, filed 7 Oct 2025.